Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

NCT02761057 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02761057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02761057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2016
Completion date
October 19, 2023
Enrollment
152 (actual)
Sites
595

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced papillary renal cell carcinoma, metastatic papillary renal cell carcinoma, stage iii renal cell cancer ajcc v7, stage iv renal cell cancer ajcc v7, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, unresectable renal cell carcinoma